Supplements

Valerian Root Benefits: 6 Uses Beyond Sleep, and Anxiety Ranks Last

·HealthyMag Editorial Team
Dried valerian roots in a pale ceramic bowl on a linen cloth

Quick Answer: Valerian root is sold mostly for sleep, and second for anxiety, but anxiety is the use with the weakest controlled evidence. The Cochrane review of valerian for anxiety disorders found just one eligible trial of 36 people, with no difference from placebo, and a 2022 network meta-analysis of 29 herbal anxiety trials found “insufficient evidence to confirm the effectiveness of Valerian.” The more consistent positive results come from small placebo-controlled trials in women: period pain (5 trials, 408 participants, pain about 1 point lower on a 10-point scale, with very high heterogeneity) and menopausal hot flashes (two trials of 68 and 60 women). Obsessive-compulsive disorder has one 31-person pilot; restless legs has one null trial. The US National Center for Complementary and Integrative Health (NCCIH) sums it up: “There is not enough evidence to determine whether valerian is useful for any health conditions.”

This page covers what valerian root has been tested for apart from sleep, what each trial actually measured, and how much root goes into a cup of valerian tea. For whether it helps you sleep, our sleep supplements guide covers the trials. For heart, liver and drug-interaction safety, see valerian root side effects.

Valerian root benefits beyond sleep: the 6 uses tested

UseBest evidence foundWhat it showed
Period pain (primary dysmenorrhea)Meta-analysis, 5 trials, 408 participants (2025)Pain lower by about 1 point on a 0-10 scale; I² 90.4%
Menopausal hot flashes2 placebo trials, 68 and 60 women (2013, 2018)Less severe hot flashes than placebo in both
Premenstrual syndrome1 placebo trial, 100 students (2016)Symptoms fell in the valerian group, not in the placebo group
Obsessive-compulsive disorder1 pilot trial, 31 adults (2011)Better than placebo after 8 weeks; somnolence more common
Restless legs syndrome1 placebo trial, 37 people (2009); 1 trial vs gabapentin, 40 people (2023)No overall difference from placebo; gabapentin did better
Anxiety disordersCochrane review, 1 trial, 36 people (2006); network meta-analysis, 29 trials (2022)No difference from placebo; “insufficient evidence”

Two things stand out. The uses with positive placebo-controlled results are all in women’s health, and every individual trial we read in those areas was run in Iran, with between 60 and 100 participants. And the use the supplement industry leans on most after sleep, anxiety, is the one where the formal reviews have nothing positive to report.

Anxiety: the most promoted use, the thinnest evidence

The NCCIH notes that “Today, valerian is promoted for insomnia, anxiety, stress, and depression.” The evidence for anxiety does not match the promotion.

Cochrane, 2006. The review searched trial registers, contacted manufacturers of valerian products and wrote to experts looking for unpublished studies. It found one randomised trial that qualified: a 4-week pilot in 36 people with generalised anxiety disorder, comparing valerian, diazepam and placebo. “There were no significant differences between the valerian and placebo groups in HAM-A total scores,” the standard clinician-rated anxiety scale. The authors concluded that “there is insufficient evidence to draw any conclusions about the efficacy or safety of valerian compared with placebo or diazepam for anxiety disorders.”

Network meta-analysis, 2022. A Beijing team pooled 29 trials of 12 herbal medicines for anxiety. Lavender oil (Silexan) and kava showed effects on the Hamilton scale. For valerian, the estimate was a mean difference of 0.95 points, with a credible interval running from -6.57 to 8.42: wide enough to include a meaningful benefit, no effect and a meaningful harm. The authors wrote that “there was insufficient evidence to confirm the effectiveness of Valerian.”

Single-dose studies before procedures. Some trials have tested valerian as a one-off calming dose. In a Brazilian trial of 54 people having two wisdom teeth removed, scores on the state anxiety scale fell between before and after surgery in the valerian and passionflower groups “unlike placebo” (p = 0.129 for the placebo group). That is a within-group change, not a head-to-head difference from placebo. In a 2019 Brazilian split-mouth crossover trial, valerian was compared with midazolam, a prescription sedative, with no placebo arm; the authors concluded that “further studies are necessary before valerian can be clinically recommended.”

The single-dose approach also sits uneasily with the European regulator. The European Medicines Agency (EMA) herbal monograph, which allows valerian extracts for “the relief of mild nervous tension and sleep disorders,” states that “because of its gradual onset of efficacy valerian root is not suitable for acute interventional treatment of mild nervous tension or sleep disorders,” and recommends “continued use over 2-4 weeks.”

Hemodialysis patients. One crossover trial in 39 people on dialysis reported larger drops in state anxiety, depression and sleep scores while on valerian than on placebo in both phases. It is the most positive anxiety result we found, but it measured anxiety as a secondary symptom in a very specific group, not anxiety disorder.

Period pain: the largest body of positive trials

The first trial, published in 2011, randomised 100 university students with painful periods to valerian (255 mg three times a day for the first 3 days of menstruation) or placebo, for two cycles. Pain fell in both groups, but “the extent of the reduction was larger in the valerian group, with the difference between the 2 groups being statistically significant (P<0.05).” The other symptoms that come with period pain, such as nausea and fatigue, did not differ between groups except fainting.

A 2025 meta-analysis pooled five controlled trials with 201 people on valerian and 207 controls. Pain was lower with valerian by a standardised mean difference of -1.03 (95% CI -1.74 to -0.33), which the authors translate as about 1 point on a 0-10 pain scale. But heterogeneity was 90.4%, meaning the trials disagreed with one another far more than chance would explain, and some compared valerian with painkillers rather than placebo. The authors call valerian “promising” and say that “further standardized RCTs are needed to confirm efficacy.”

One detail worth knowing: the first author of the 2011 trial, P. Mirabi, is also an author of the 2013 hot flash trial below and of the 2025 meta-analysis that pooled the period pain trials.

Hot flashes: two small trials, both positive

In a 2013 double-blind trial, 68 menopausal women took 255 mg valerian capsules three times a day, or starch placebo, for 8 weeks. The severity of hot flashes after treatment differed between groups (p < 0.001), and frequency fell at 4 and 8 weeks with valerian but not with placebo.

A 2018 triple-blind trial in Hamadan gave 60 postmenopausal women aged 45 to 55 either 530 mg of valerian twice a day or placebo for two months. Hot flash severity was lower with valerian at one month (p = .048) and two months (p = .020), and frequency was lower at two months (p = .033).

Both trials point the same way, which is more than most valerian uses can claim. Both are also small, single-centre and short, and neither compared valerian with hormone therapy or the non-hormonal drugs that have much larger trial records. The 2018 authors’ recommendation that providers “should consider Valerian to be effective” goes further than two trials of this size support.

Premenstrual syndrome, OCD and restless legs

Premenstrual syndrome. A 2016 trial randomised 100 female students with PMS to two valerian tablets daily for the last seven days of the cycle, or placebo, over three cycles. Emotional, behavioural and physical symptom scores fell in the valerian group (P < 0.001), and “this difference was not statistically significant in the control group.” The abstract reports these before-and-after changes within each group rather than a direct comparison of the groups, which is a weaker form of evidence.

Obsessive-compulsive disorder. An 8-week Iranian pilot gave 31 adults with OCD either valerian extract (765 mg a day) or placebo. Scores differed between groups at the end of treatment, and somnolence was the only side effect that differed. The authors described it as a pilot and wrote that “further studies are needed to confirm these findings.” No larger trial has followed in the 15 years since.

Restless legs syndrome. A US triple-blind trial gave 37 people 800 mg of valerian or placebo for 8 weeks. “Both groups reported improvement in RLS symptom severity and sleep.” The positive findings came from a nested analysis of the 17 people on valerian, split by how sleepy they were at the start. In a 2023 crossover trial in 40 dialysis patients, the authors concluded that “Gabapentin is more effective than valerian in improving RLS.”

Valerian root tea: how much root is in a cup

The EMA monograph is the clearest dose guidance available, and it covers tea directly. For traditional use “for relief of mild symptoms of mental stress and to aid sleep,” the herbal tea dose is 0.3 to 3 g of cut root “in 150 ml of boiling water as a herbal infusion.” That is a tenfold range, so two cups of valerian tea can differ in strength as much as one capsule differs from ten. For stress, the monograph allows a dose up to 3 times a day; for sleep, one dose half an hour to an hour before bed, with an earlier dose in the evening if needed.

For extracts, the “well-established use” dose is 400 to 600 mg of dry extract per dose. The trials above used 255 to 530 mg per capsule, mostly powdered root, which is not the same thing as a concentrated extract. The monograph also says use “in children under 12 years of age is not recommended,” and that anyone whose symptoms “persist or worsen after 2 weeks of continued use” should see a doctor or pharmacist.

The EMA’s legal category matters here. “Traditional use” means a product is registered “exclusively based upon long-standing use,” not on clinical trials. Tea preparations fall in that category; the 2-4 week course and the extract doses sit under “well-established use.”

Advertisement

Herbal Lab Valerian Root Extract. A liquid valerian root extract in an alcohol-free glycerin base, listed at 1,000 mg of botanical extract per 1 ml serving. This is a paid placement, not a recommendation: none of the trials on this page tested a liquid glycerin extract, and the label does not state an extract ratio or valerenic acid content, so its strength cannot be compared with the capsules used in the period pain and hot flash trials or with the EMA’s 400 to 600 mg dry extract dose.

View on Herbal Lab (code HERBAL15)

Sponsored link — we may earn a commission at no extra cost to you. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Do not combine with alcohol, sleeping pills or other sedatives, and if you take prescription medicine, are having surgery, or are pregnant or breastfeeding, ask your doctor or pharmacist first.

What the evidence adds up to

Valerian has been in use since ancient Greece and Rome, and the NCCIH lists insomnia, migraine, fatigue and stomach cramps among its historical uses. Modern trials have tested only a few of those claims, and the pattern is not the one most product pages suggest:

  • Women’s health uses (period pain, hot flashes, PMS) have small positive trials, all from one country, several sharing an author. They are a reason for a larger trial, not a settled answer.
  • Anxiety, the use most often printed on labels after sleep, has a Cochrane review with one qualifying trial and a null result, and a network meta-analysis that could not separate valerian from no effect.
  • Restless legs did not beat placebo overall, and lost to gabapentin.
  • OCD rests on one pilot of 31 people.

If you have heavy period pain, menopausal symptoms, an anxiety disorder or OCD, each has established treatments that have been tested in larger trials, and a doctor can weigh valerian against them. Valerian’s side effects and its interactions with sedatives, alcohol and anaesthesia are covered on our side effects page.

Frequently Asked Questions

What is valerian root good for?

Valerian root is mainly used for sleep, and is also promoted for anxiety and stress. Outside sleep, the more consistent positive trials are small studies in women: period pain (five trials pooled, about 1 point less pain on a 10-point scale) and menopausal hot flashes (two trials of 68 and 60 women). The NCCIH says there is “not enough evidence to determine whether valerian is useful for any health conditions.”

Does valerian root help with anxiety?

The formal reviews have not found that it does. The Cochrane review found one eligible trial of 36 people with generalised anxiety disorder and no difference from placebo. A 2022 network meta-analysis of 29 herbal anxiety trials found “insufficient evidence to confirm the effectiveness of Valerian.”

Does valerian root work right away?

The European Medicines Agency says that “because of its gradual onset of efficacy valerian root is not suitable for acute interventional treatment” of nervous tension or sleep problems, and recommends continued use over 2 to 4 weeks for its well-established uses.

Can valerian root help with period cramps?

Small trials suggest it may. A 2025 meta-analysis of five trials with 408 participants found pain about 1 point lower on a 0-10 scale, but the trials varied widely (heterogeneity 90.4%), and the authors call for “further standardized RCTs.” The trials used 255 mg three times a day during the first days of menstruation.

How much valerian root is in a cup of tea?

The EMA monograph sets the herbal tea dose at 0.3 to 3 g of cut root in 150 ml of boiling water, a tenfold range. For stress it allows up to three doses a day; for sleep, one dose half an hour to an hour before bed.

Is valerian root good for menopause?

Two small Iranian trials found less severe hot flashes with valerian than with placebo: 68 women on 255 mg three times a day for 8 weeks, and 60 women on 530 mg twice a day for two months. Neither compared valerian with hormone therapy or other proven treatments.

Sources

  1. Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD004515. PubMed 17054208. One RCT, 36 patients with generalised anxiety disorder, 4 weeks, valerian vs diazepam vs placebo; no significant differences in HAM-A. Abstract. Checked 8 November 2026.
  2. Zhang W, et al. Medicinal herbs for the treatment of anxiety: a systematic review and network meta-analysis. Pharmacol Res. 2022;179:106204. PubMed 35378276. 29 trials, 12 herbs; valerian MD 0.95 (95% CrI -6.57 to 8.42). Abstract. Checked 8 November 2026.
  3. Velasquez ACA, et al. Effects of Passiflora incarnata and Valeriana officinalis in the control of anxiety due to tooth extraction: a randomized controlled clinical trial. Oral Maxillofac Surg. 2024;28(3):1313-1320. PubMed 38743126. 54 patients, 3 groups; placebo p = .129. Abstract. Checked 8 November 2026.
  4. Farah GJ, et al. Assessment of Valeriana officinalis L. (valerian) for conscious sedation of patients during the extraction of impacted mandibular third molars: a randomized, split-mouth, double-blind, crossover study. J Oral Maxillofac Surg. 2019;77(9):1796.e1-1796.e8. PubMed 31158346. Compared with midazolam, no placebo arm; “further studies are necessary.” Abstract. Checked 8 November 2026.
  5. Tammadon MR, et al. The effects of valerian on sleep quality, depression, and state anxiety in hemodialysis patients: a randomized, double-blind, crossover clinical trial. Oman Med J. 2021;36(2):e255. PubMed 33936782. 39 patients. Abstract. Checked 8 November 2026.
  6. Mirabi P, Dolatian M, Mojab F, Majd HA. Effects of valerian on the severity and systemic manifestations of dysmenorrhea. Int J Gynaecol Obstet. 2011;115(3):285-8. PubMed 21959068. 100 students (49 valerian, 51 placebo), 255 mg three times daily for 3 days, 2 cycles; P<0.05. Abstract. Checked 8 November 2026.
  7. Rabiei F, Delavar MA, Mirabi P, et al. Effect of Valeriana officinalis on primary dysmenorrhea: a systematic review and meta-analysis. Rev Recent Clin Trials. 2025. PubMed 40965071. 5 trials, 201 intervention and 207 control; SMD -1.03 (-1.74 to -0.33); I² 90.40%. Abstract. Checked 8 November 2026.
  8. Mirabi P, Mojab F. The effects of valerian root on hot flashes in menopausal women. Iran J Pharm Res. 2013;12(1):217-22. PubMed 24250592. 68 women, 255 mg three times daily for 8 weeks; severity p < 0.001. Abstract. Checked 8 November 2026.
  9. Jenabi E, Shobeiri F, Hazavehei SMM, Roshanaei G. The effect of Valerian on the severity and frequency of hot flashes: a triple-blind randomized clinical trial. Women Health. 2018;58(3):297-304. PubMed 28278010. 60 women aged 45-55, 530 mg twice daily for two months; severity p = .048 and .020, frequency p = .033. Abstract. Checked 8 November 2026.
  10. Behboodi Moghadam Z, et al. The effect of Valerian root extract on the severity of pre menstrual syndrome symptoms. J Tradit Complement Med. 2016;6(3):309-15. PubMed 27419099. 100 students, 3 cycles; within-group P < 0.001. Abstract. Checked 8 November 2026.
  11. Pakseresht S, Boostani H, Sayyah M. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med. 2011;8. PubMed 22718671. 31 adults, 765 mg/day, 8 weeks. Abstract. Checked 8 November 2026.
  12. Cuellar NG, Ratcliffe SJ. Does valerian improve sleepiness and symptom severity in people with restless legs syndrome? Altern Ther Health Med. 2009;15(2):22-8. PubMed 19284179. 37 participants, 800 mg for 8 weeks; nested analysis n=17. Abstract. Checked 8 November 2026.
  13. Hajizadeh I, et al. Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: a randomized clinical trial. Ther Apher Dial. 2023;27(4):621-628. PubMed 37039703. 40 patients, crossover. Abstract. Checked 8 November 2026.
  14. European Medicines Agency, Committee on Herbal Medicinal Products. European Union herbal monograph on Valeriana officinalis L., radix. EMA/HMPC/150848/2015, Corr. 1; adopted 2 February 2016. ema.europa.eu (PDF). Indications, 400-600 mg dry extract, tea 0.3-3 g in 150 ml, 2-4 weeks, under 12 not recommended. Checked 8 November 2026.
  15. National Center for Complementary and Integrative Health. Valerian. nccih.nih.gov. Checked 8 November 2026.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions. Content reviewed by the HealthyMag Editorial Team.

Related